RSC medicinal chemistry

Five years of research on 2,4-thiazolidinediones as cancer-fighting drugs: chemistry insights (2020-2024)

Updated

Abstract

2,4-Thiazolidinedione derivatives have shown promise as anticancer agents by influencing key molecular pathways involved in tumor development.

  • 2,4-TZDs traditionally recognized for antidiabetic properties are now being explored for their potential in cancer treatment.
  • These compounds can affect processes such as cell growth, programmed cell death, blood vessel formation, and cancer spread.
  • Structural modifications at the C-5 position of 2,4-TZDs allow for adjustments in their biological activity and targeting capabilities.
  • Recent evaluations (2020-2024) highlight how different chemical changes impact the effectiveness and selectivity of these compounds against cancer cells.
  • Insights into the molecular mechanisms of selected 2,4-TZD derivatives provide a deeper understanding of their anticancer effects.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free